Cargando…

Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model

BACKGROUND: Therapeutic human papillomavirus (HPV) vaccines are currently being developed. However, no therapeutic efficacy has been achieved in clinical trials for the treatment of cervical intraepithelial neoplasia or cancer. One of the important issues in increasing vaccine efficacy is determinin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chu, Xiaojie, Li, Yang, Long, Qiong, Xia, Ye, Yao, Yufeng, Sun, Wenjia, Huang, Weiwei, Yang, Xu, Liu, Cunbao, Ma, Yanbing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892837/ https://www.ncbi.nlm.nih.gov/pubmed/27313455 http://dx.doi.org/10.2147/IJN.S102467

Ejemplares similares

Generation of fusion protein EGFRvIII-HBcAg and its anti-tumor effect in vivo
por: Duan, Xiao-yi, et al.
Publicado: (2009)

Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor
por: Wang, Shijie, et al.
Publicado: (2017)

Exosomes from Ub‑HBcAg‑overexpressing dendritic cells induce T‑lymphocyte differentiation and enhance cytotoxic T‑lymphocyte activity
por: Yang, Yuhang, et al.
Publicado: (2023)

Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide
por: Schumacher, Jens, et al.
Publicado: (2018)

Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
por: Shiraishi, Kana, et al.
Publicado: (2023)

Incidencia de HBcAg en donadores de sangre hospital general de zona No. 32, Minatitlán, Ver.
por: Pérez García, Eduardo
Publicado: (1995)

Parenteral–Oral Immunization with Plant-Derived HBcAg as a Potential Therapeutic Vaccine against Chronic Hepatitis B
por: Pyrski, Marcin, et al.
Publicado: (2019)

Studies on HBcAg-rBlo t 5-21 Fusion Protein Vaccine That Alleviates Blomia tropicalis Airway Inflammation
por: Pei, Yechun, et al.
Publicado: (2022)

In vitro expression of precore proteins of hepatitis B virus subgenotype A1 is affected by HBcAg, and can affect HBsAg secretion
por: Deroubaix, Aurélie, et al.
Publicado: (2021)

Negative HBcAg in immunohistochemistry assay of liver biopsy is a predictive factor for the treatment of patients with nucleos(t)ide analogue therapy
por: Huang, Mingxing, et al.
Publicado: (2017)

Removal of Hepatitis B virus surface HBsAg and core HBcAg antigens using microbial fuel cells producing electricity from human urine
por: Pasternak, Grzegorz, et al.
Publicado: (2019)

Effects of Different Lengths of a Nucleic Acid Binding Region and Bound Nucleic Acids on the Phase Behavior and Purification Process of HBcAg Virus-Like Particles
por: Valentic, Angela, et al.
Publicado: (2022)

Self-Assembled Nanofibers Elicit Potent HPV16 E7-Specific Cellular Immunity And Abolish Established TC-1 Graft Tumor
por: Li, Sijin, et al.
Publicado: (2019)

The Fusion Protein of CTP-HBcAg18-27-Tapasin Mediates the Apoptosis of CD8(+)T Cells and CD8(+) T Cell Response in HLA-A2 Transgenic Mice
por: Tang, Yu-Yan, et al.
Publicado: (2014)

Application of In-Situ and Soft-Sensors for Estimation of Recombinant P. pastoris GS115 Biomass Concentration: A Case Analysis of HBcAg (Mut(+)) and HBsAg (Mut(S)) Production Processes under Varying Conditions
por: Grigs, Oskars, et al.
Publicado: (2021)

Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021)

High-level production of recombinant HBcAg virus-like particles in a mathematically modelled P. pastoris GS115 Mut(+) bioreactor process under controlled residual methanol concentration
por: Bolmanis, Emils, et al.
Publicado: (2022)

Immunization against Multidrug-Resistant Acinetobacter baumannii Effectively Protects Mice in both Pneumonia and Sepsis Models
por: Huang, Weiwei, et al.
Publicado: (2014)

Immunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii
por: Huang, Weiwei, et al.
Publicado: (2016)

Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients
por: Cerva, Carlotta, et al.
Publicado: (2022)

Employing Escherichia coli-derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against Acinetobacter baumannii infection
por: Huang, Weiwei, et al.
Publicado: (2016)

Evaluation of HBs-Ag and anti-HBc levels in serum and saliva of patients with hepatitis B
por: Gharavi, Matine, et al.
Publicado: (2020)

Prevalence of HBc-Ab among HBs-Ag negative healthy blood donors in south of Iran
por: Khorami, Farhad, et al.
Publicado: (2013)

De novo hepatitis B surface antigen (HBsAg)-positive, core antibody (anti-HBc)-negative, hepatitis B virus infection post-liver transplant from an anti-HBc, HBsAg-negative donor
por: Bedi, Harjot K., et al.
Publicado: (2021)

Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates
por: Kazaks, Andris, et al.
Publicado: (2017)

Designing of multi-epitope chimeric vaccine using immunoinformatic platform by targeting oncogenic strain HPV 16 and 18 against cervical cancer
por: Kumar, Anoop, et al.
Publicado: (2022)

Design of a Novel and Potent Multi-Epitope Chimeric Vaccine against Human Papillomavirus (HPV): An Immunoinformatics Approach
por: Shahab, Muhammad, et al.
Publicado: (2023)

Prevalence of Anti-HBc Antibodies among HBsAg Negative Individuals and Its Association with Occult Hepatitis B
por: Madhavan, Anitha, et al.
Publicado: (2021)

Beam position for the 2m HBC
por: Perreau, J M, et al.
Publicado: (1964)

Report on the future program for the HBC 200
por: CERN. Geneva. Track Chamber Committee
Publicado: (1975)

Memorandum : HBC 200 Camera Window
por: Stierlin, R G, et al.
Publicado: (1975)

Geometry titles for the 2m HBC
por: Kellner, G
Publicado: (1969)

Isolated Anti-HBc: Significance and Management
por: MORETTO, Florian, et al.
Publicado: (2020)

Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(−)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis
por: Kuo, Meng Hsuan, et al.
Publicado: (2020)

Cost‐effective purification process development for chimeric hepatitis B core (HBc) virus‐like particles assisted by molecular dynamic simulation
por: Zhang, Bingyang, et al.
Publicado: (2021)

A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection
por: Monroy-García, Alberto, et al.
Publicado: (2011)

Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance
por: Kim, Saein, et al.
Publicado: (2021)

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis
por: Morisco, Filomena, et al.
Publicado: (2014)

RE: Risk of HBV Reactivation in HBsAg Negative and Anti-HBc IgG Positive Patients Receiving Biologic Therapy
por: Ergenç, İlkay, et al.
Publicado: (2023)

Test on double pulsing of the 2m HBC
por: Blumenfeld, H, et al.
Publicado: (1970)

Cannot write session to /tmp/vufind_sessions/sess_35687gra6faj4v4mujmstfsc6c